Article Per Year (5 Year)
p-Index From 2020 - 2025
0
P-Index
This Author published in this journals
All Journal The Journal of Experimental Life Sciences (JELS)
Muhaimin Rifa'i
Dept. of Biology, University of Brawijaya
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
The Potential of EMSA Eritin to Modulate T Cells (CD4+ and CD8+) in Balb/C Mice Model of Diabetes Mellitus Ade MC Rohie; Muhaimin Rifa'i
The Journal of Experimental Life Science Vol. 5 No. 1 (2015)
Publisher : Postgraduate School, Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1181.883 KB) | DOI: 10.21776/ub.jels.2015.005.01.08

Abstract

EMSA Eritin is a medicinal polyherbal contains with soy bean, coconut water and red rice extract. In several studies of this individual components have proven the potential to modulate lymphocyte cells that indirectly lowering blood glucose levels in diabetes meliitus. This study was aimed to analyzing the effect of polyherbal EMSA Eritin on the expression of CD4+, CD8+ and SDF-1 cells population in mice model of diabetes mellitus. Neonatal d-5 mice was intraperitoneally injected with Streptozotocin (STZ) 100 mg.kg-1 BW. Four weeks post injection the mice was treated with EMSA Eritin in three doses 0.3125 mg.g-1 BW, 3.125 mg.g-1 BW and 31.25 mg.g-1 BW for 14 days. Cells Profile of T lymphocyte (CD4+ and CD8+) and chemokine SDF-1 were analyzed by Flow cytometry. Data were analyzed with One-way ANOVA (p<0.05) and Duncan test using SPSS 16.0 for Windows. The result showed that EMSA Eritin significantly increased T lymphocyte (CD4+ and CD8+) in optimum dose 3.125 mg.g-1 BW and suppress SDF-1 production in high dose (31.25 mg.g-1 BW) as well as the blood glucose level measurement. This study suggest that polyherbal EMSA Eritin has a potential to decreased blood glucose level in mice model of diabetes mellitus.Keywords: CD4+, CD8+, diabetes mellitus, EMSA Eritin, SDF-1
EMSA Eritin Blocks Nuclear Factor-Kappa B in Diabetes Mellitus Mice Model Maic Audo Lin Sihombing; Sutiman B. Sumitro; Muhaimin Rifa'i
The Journal of Experimental Life Science Vol. 5 No. 1 (2015)
Publisher : Postgraduate School, Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1025.231 KB) | DOI: 10.21776/ub.jels.2015.005.01.05

Abstract

Diabetes mellitus is one of the common metabolic disorders with increasing prevalence during recent years with hyperglycemia as its characteristic. DM has been shown to be a state of free radicals over production resulted from hyperglycemia that can activate cellular signaling pathways transcription of factor NF-κB which stimulates the production of several inflammatory mediators andl lead to chronic inflammation. Chronic inflammation is implicated in β-cell damage and function and promotes apoptosis. EMSA Eritin is a polyherbal consisting of soy bean extracts, coconut water extract and red rice extract that assumed to be antidiabetic and anti-inflammatory. This study will assess the effectiveness of EMSA Eritin against inflammation in diabetes mellitus by measuring levels of NF-κB produced by immunocompetent cells in DM mice model. Streptozotocin 100 mg.kg-1 BW is used to induce diabetes mellitus in mice. Oral administration of EMSA Eritin was given for 14 days with dose of 0.3125 mg.g-1 BW, 3.125 mg.g-1 BW and 31.25 mg.g-1 BW. Data were analyzed using One-way ANOVA (p<0.05) and Duncan test using SPSS 16.0 for Windows. The results showed that EMSA Eritin can be used as an alternative therapy for the treatment of DM. The level of NF-κB in diabetic mice significantly decreased when the mice received EMSA Eritin. Keywords: Diabetes Mellitus, EMSA Eritin, NF-κB, ROS
Co-Authors Ade MC Rohie Maic Audo Lin Sihombing Sutiman B. Sumitro